SCHEMBL3767997

SCHEMBL3767997

Cc1ccccc1N1CCN(CC(=O)N2CCN(C3CCC3)CC2)CC1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.53
KMT2A Q03164 4/20 0.51
POLB P06746 1/20 0.51
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 3/20 0.50
AR P10275 2/20 0.50
MAPT P10636 2/20 0.50
ALOX15 P16050 2/20 0.50
HSD17B10 Q99714 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
MEN1 O00255 1/20 0.50
TP53 P04637 1/20 0.50
MAPK1 P28482 1/20 0.50
SLC18A3 Q16572 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3774214 0.98 TSHR (0.56) TSHRKMT2APOLBALDH1A1KDM4E
SCHEMBL3763088 0.97 TSHR (0.58) TSHRKMT2APOLBALDH1A1KDM4E
SCHEMBL20122620 0.97 TSHR (0.58) TSHRKMT2APOLBALDH1A1KDM4E
SCHEMBL3774250 0.92 MAPT (0.60) TSHRKMT2APOLBALDH1A1KDM4E
SCHEMBL3775910 0.90 MAPT (0.60) TSHRKMT2APOLBALDH1A1KDM4E
SCHEMBL3772561 0.87 ALDH1A1 (0.52) TSHRKMT2APOLBALDH1A1KDM4E
SCHEMBL3767597 0.87 HTR7 (0.52) TSHRKMT2APOLBALDH1A1KDM4E
SCHEMBL3772241 0.86 SMN1; SMN2 (0.61) TSHRKMT2APOLBALDH1A1MAPT
SCHEMBL3767940 0.86 SMN1; SMN2 (0.50) TSHRKMT2APOLBALDH1A1MAPT
SCHEMBL3768876 0.86 KMT2A (0.56) TSHRKMT2AALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 TSHR 436/4885KMT2A 242/4885POLB 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.